Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).

Published 2022 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non–small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 40, Issue 16_suppl, Pages 9032-9032
Publisher
American Society of Clinical Oncology (ASCO)
Online
2022-06-07
DOI
10.1200/jco.2022.40.16_suppl.9032

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.